Recent Updates
Recently added Catalysts

Tomotherapy

Phase 2

Mesothelioma | Unknown | Oncology |Avalon GloboCare Corp.|Last Updated: Apr 6, 2016

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDDMC
Total Trials1
Total Enrollment18

FDA Designations

No designations recorded

Clinical trial landscape

Tomotherapy · 3 trials · 3 indications

Phase 2 1Phase 1 2
NCT00469196Tomotherapy Treatment for MesotheliomaMesothelioma
COMPLETED18 Analytics
PHASE2COMPLETED
Tomotherapy Treatment for Mesothelioma
MesotheliomaUnlock trial analytics

Study Endpoints

Primary Endpoints

Quality of Life
6 months

Disease-specific symptom control rate post-treatment, based on Palliation Index \[7\].

safety and adverse effects
Trial Completion
safety and adverse events

Secondary Endpoints

Breathing Function
6 months
Survival/Response Rate
6 months
efficacy and survival
Trial completion
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Interventions

NameTypeDescription
TomotherapyPROCEDURE40 Gy in 15 fractions, at one fraction per day. Dose will be prescribed to the 95% isodose line.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * histologic mesothelioma * refused/ineligible for surgery or chemotherapy * life expectancy \>3 months Exclusion Criteria: * contraindications to thoracic radiotherapy * unable to lie flat for duration of radiation therapy

Countries:Canada
Unlock Eligibility Criteria

Frequently asked questions about Tomotherapy

What is Tomotherapy used for?

Tomotherapy is an investigational radiation therapy approach being studied for use in mesothelioma, brain neoplasms, and non-small-cell lung carcinoma. It is a form of image-guided intensity-modulated radiation therapy that delivers precise radiation doses to tumors while sparing surrounding healthy tissue. Tomotherapy is still in clinical development and is not yet approved by the FDA.

Who is developing Tomotherapy?

Tomotherapy is being developed by Avalon GloboCare Corp., a biopharmaceutical company traded on the stock exchange under the ticker ALBT. The company is conducting clinical trials to evaluate the safety and efficacy of Tomotherapy in various oncology indications, including brain tumors, lung cancer, and mesothelioma.

What phase is Tomotherapy in?

Tomotherapy is in Phase 1 clinical development. Clinical trials have been completed for brain neoplasms and non-small-cell lung carcinoma, with a Phase 2 trial also completed for mesothelioma. However, Tomotherapy remains investigational and has not received regulatory approval for any indication.

What clinical trials is Tomotherapy in?

Tomotherapy has been studied in three completed clinical trials. NCT00128986 evaluated Tomotherapy in patients with benign brain tumors, NCT00129012 studied a self-gated breath-hold technique for helical Tomotherapy in non-small-cell lung cancer, and NCT00469196 assessed Tomotherapy treatment for mesothelioma. All trials were conducted in Canada.

Is Tomotherapy the same as helical tomotherapy?

Tomotherapy is a form of helical tomotherapy, a type of intensity-modulated radiation therapy that delivers radiation in a helical pattern. The clinical trials for Tomotherapy include studies of helical Tomotherapy techniques, such as the self-gated breath-hold technique for lung cancer. Tomotherapy is an investigational approach and not yet approved.